Bayer CEO Is Confident on Monsanto, 2017 Growth

The transcript discusses the company's confidence in maintaining earnings momentum and growth in 2017, driven by strong performance in pharma, consumer health, and other sectors. It addresses concerns about the Monsanto deal, highlighting progress in financing and regulatory discussions. The company also discusses its strong cash flow and the lack of recent contact with Warren Buffett. Finally, it outlines challenges in the European market and emphasizes growth opportunities in Asia and the US.

What is the company's growth expectation for 2017?

• Double-digit growth

• Low single-digit growth

• No growth

• Negative growth

How much of a stake does the company hold in Covestro?

• 64%

• 75%

• 100%

• 50%

What is a major concern regarding the Monsanto deal?

• Product recalls

• Lack of financing

• Regulatory delays

• Increased competition

Which regions are highlighted for growth opportunities?

• South America and Australia

• Asia and the US

• Europe and Africa

• Middle East and Canada

What is the company's approach to product development?

• Focus on cost reduction

• Emphasize innovation-driven products

• Prioritize market saturation

• Limit to existing product lines